Biomerica Inc (BMRA) - התחייבויות לטווח ארוך להון

Biomerica, Inc. (BMRA) is expanding its business in the laboratory diagnostics sector, where scaling has reached a stable level due to cost automation. However, regulatory delays in launching new tests and competition from innovative analysis methods are hindering expansion. The current figure is 0.47. This chart of the company's market valuation clearly demonstrates the impact of global trade barriers and geopolitical risks on equipment supply chains.

Biomerica, Inc. is scaling the production of diagnostic tests within a stable geopolitical environment devoid of sanctions risks. The long-term debt-to-equity ratio reflects the company's degree of reliance on borrowed funds with maturities exceeding one year. This metric compares long-term liabilities against net shareholders' equity to assess financial stability. A decrease in this ratio strengthens the balance sheet but may signal a slowdown in expansion. A rational balance of borrowings confirms the investment reliability of the issuer.